Evaluation of the intracellular signaling activities of κ opioid receptor agonists, nalfurafine analogs; focusing on the selectivity of G protein- and β-arrestin-mediated pathways
Year: 2023
Type: article
Abstract: Opioid receptors (ORs) are classified into three types (μ, δ, and κ), and opioid analgesics are mainly mediated by μOR activation; however, their use is sometimes restricted by unfavorable effects.The selective κOR agonist nalfurafine was initially developed as an analgesic, but its indication was changed because of the narrow safety margin.The activation of ORs mainly induces two intracellular signaling pathways: a G-protein-mediated pathway and a β-arrestin-mediated pathway.Recently, the expectations for κOR analgesics that selectively activate these pathways have increased; however, the structural properties required for the selectivity of nalfurafine are still unknown.Therefore, we evaluated the partial structures of nalfurafine that are necessary for the selectivity of these two pathways.We assayed the properties of nalfurafine and six nalfurafine analogs (SYKs) using cells stably expressing κORs.The SYKs activated κORs in a concentration-dependent manner with higher EC50 values than nalfurafine.Upon bias factor assessment, only SYK-309 (possessing the 3S-hydroxy group) showed higher selectivity of G-protein-mediated signaling activities than nalfurafine, suggesting the direction of the 3S-hydroxy group may affect the β-arrestin-mediated pathway.In conclusion, nalfurafine analogs having a 3S-hydroxy group, such as SYK-309, could be considered G-protein-biased κOR agonists.
Authors: 山口, 政広, ヤマグチ, マサヒロ
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: green
Awards: Establishment of optimal sequential administration of opioids based on the intracellular localization of opioid receptors and its changes in activity, Development of novel mu-opioid receptor-selective opioids with less adverse effects, Development of novel, specific heterodimerized opioid agonists with less tolerance and side effects
OpenAlex ID: W7093549758
